Adam Denley

Adam is a Trans-Tasman registered patent attorney specialising in the drafting and prosecution of global patent families related to the biotechnology and pharmaceutical fields. 

With a lifelong passion for the potential of medical innovation to change lives, Adam uses his extensive technical and commercial expertise to take groundbreaking medical patents from conception through to reality.

Highly regarded for his collaborative approach, he works closely with companies and researchers to capture their commercially valuable IP. He specialises in building complex patent portfolios which are both attractive to investors and able to withstand the rigours of prosecution and enforcement.

Adam provides tailored commercial advice on the basis of a thorough understanding of his clients’ inventions and business goals. He regularly works with investors to conduct due diligence work on patent families, identifying and advising on any risks that arise.

Adam also provides strategic advice to his clients regarding the enforcement and defence of patent rights, and regularly leads oppositions before the Australian Patent Office.

Before joining FPA, Adam spent nearly three years as a postdoctoral fellow in the Department of Molecular and Experimental Medicine at The Scripps Research Institute in La Jolla, USA. His research was focused on protein and lipid kinases in cell transformation, and identifying small molecules as potential lead compounds for cancer therapeutics.

Adam regularly writes articles on the interface between biotechnology and patent law, with a particular focus on therapeutic antibodies, diagnostics, isolated nucleic acids and biomarkers.

Adam has authored 14 peer reviewed articles and reviews in journals such as Molecular and Cellular Biology, The EMBO Journal and the Proceedings of the National Academy of Science of the United States of America. Articles can be viewed at the US National Library of Medicine, National Institutes of Health (PubMed).